logo-loader

Allergy Therapeutics' set for phase III trial after positive results from grass pollen immunotherapy

Published: 15:51 25 Oct 2021 BST

Allergy Therapeutics PLC (AIM:AGY) (LON:AGY) Head of Business Innovation Alan Bullimore caught up with Proactive London to talk about the results from a study targeting grass pollen allergies. 

The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.

As he explains there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

40 minutes ago